IT1246777B
(it)
*
|
1991-04-12 |
1994-11-26 |
Boehringer Mannheim Italia |
Aminoacil derivati di acidi gem-difosfonici,un processo per la loro preparazione e composizioni farmaceutiche che li contengono
|
IT1246778B
(it)
*
|
1991-04-12 |
1994-11-26 |
Boehringer Mannheim Italia |
Nitrosocarbamoil derivati di acidi gem-difosfonici, un processo per la loro preparazione e composizioni farmaceutiche che li contengono
|
US5270365A
(en)
*
|
1991-12-17 |
1993-12-14 |
Merck & Co., Inc. |
Prevention and treatment of periodontal disease with alendronate
|
US6399592B1
(en)
|
1992-12-23 |
2002-06-04 |
Merck & Co., Inc. |
Bishphosphonate/estrogen synergistic therapy for treating and preventing bone loss
|
US5510517A
(en)
*
|
1993-08-25 |
1996-04-23 |
Merck & Co., Inc. |
Process for producing N-amino-1-hydroxy-alkylidene-1,1-bisphosphonic acids
|
TW257765B
(de)
*
|
1993-08-25 |
1995-09-21 |
Merck & Co Inc |
|
US5462932A
(en)
*
|
1994-05-17 |
1995-10-31 |
Merck & Co., Inc. |
Oral liquid alendronate formulations
|
US5449819A
(en)
*
|
1994-06-06 |
1995-09-12 |
Merck & Co., Inc. |
Process for removing waste pox, alendronate and its by products
|
US5589691A
(en)
*
|
1994-06-06 |
1996-12-31 |
Merck & Co., Inc. |
Process for recovery and recycle of methanesulfonic acid and phosphorous acid
|
US5780455A
(en)
*
|
1994-08-24 |
1998-07-14 |
Merck & Co., Inc. |
Intravenous alendronate formulations
|
EP0809502A4
(de)
*
|
1995-02-17 |
2001-12-05 |
Merck & Co Inc |
Verfahren zur verminderung des risikos nicht-vertebraler knochenbrüche
|
TW393488B
(en)
*
|
1995-04-20 |
2000-06-11 |
Merck & Co Inc |
Process for making 1-hydrox-ybisphosphonates
|
EP0824341A4
(de)
*
|
1995-05-12 |
1999-07-07 |
Merck & Co Inc |
Vorbeugung gegen zahnverlust durch verabreichung von alendronat oder dessen salze
|
ATE289199T1
(de)
*
|
1995-06-06 |
2005-03-15 |
Merck & Co Inc |
Formulierungen mit dem wasserfreien mononatriumsalz von alendronat und deren verwendung zur behandlung von knochenkrankheiten
|
EP0831756A1
(de)
|
1995-06-06 |
1998-04-01 |
Merck & Co., Inc. |
Bisphosphonat-zementzusammensetzung zur verhinderung von aseptischer lockerung orthopädischer prothesen
|
KR100192215B1
(ko)
*
|
1996-09-03 |
1999-06-15 |
강재헌 |
3-아미노-1-히드록시프로판-1,1-디포스폰산의 제조방법
|
AU723357B2
(en)
*
|
1996-10-04 |
2000-08-24 |
Merck & Co., Inc. |
Liquid alendronate formulations
|
CA2197267C
(en)
*
|
1997-02-11 |
2000-02-08 |
Yong Tao |
Process for the production of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
|
BR9910074A
(pt)
|
1998-04-29 |
2000-12-26 |
Procter & Gamble |
Processo para fabricação de uréias 1,3-di-substituìdas-4-oxocìclicas
|
NZ506773A
(en)
|
1998-04-29 |
2004-03-26 |
Procter & Gamble |
Process for making 1, 3-disubstituted-4-oxocyclic ureas
|
US6432931B1
(en)
|
1998-06-24 |
2002-08-13 |
Merck & Co., Inc. |
Compositions and methods for inhibiting bone resorption
|
US20030078211A1
(en)
*
|
1998-06-24 |
2003-04-24 |
Merck & Co., Inc. |
Compositions and methods for inhibiting bone resorption
|
US6008207A
(en)
*
|
1998-08-13 |
1999-12-28 |
Merck & Co., Inc. |
Anhydrous alendronate monosodium salt formulations
|
RO122854B1
(ro)
*
|
1998-08-27 |
2010-03-30 |
Teva Pharmaceutical Industries Ltd. |
Alendronat de sodiu hidrat, procedeu de obţinere şi compoziţie farmaceutică
|
EP1702924A3
(de)
*
|
1998-08-27 |
2007-07-18 |
Teva Pharmaceutical Industries Ltd |
Hydratformen des Natriumsalzes von Alendronat, Verfahren zu ihrer Herstellung und pharmazeutische Zusammensetzungen
|
US6331533B1
(en)
|
1998-11-16 |
2001-12-18 |
Merck & Co., Inc. |
Method for inhibiting dental resorptive lesions
|
KR100327786B1
(ko)
*
|
1999-03-25 |
2002-03-14 |
유승필 |
4-아미노-1-하이드록시부틸리덴-1,1-비스포스폰산 또는 이의 염의 제조방법
|
US6143919A
(en)
*
|
1999-05-18 |
2000-11-07 |
3M Innovative Properties Company |
Polymerizable acidic compounds and methods of preparation
|
US6315566B1
(en)
|
1999-05-18 |
2001-11-13 |
3M Innovative Properties Company |
Dental materials
|
US6963008B2
(en)
*
|
1999-07-19 |
2005-11-08 |
Teva Pharmaceutical Industries Ltd. |
Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
|
ES2153794B1
(es)
*
|
1999-08-06 |
2001-10-16 |
Medichem Sa |
Procedimiento para la obtencion del acido 4-amino-1-hidroxibutiliden-1,1-bisfosfonico y de su sal monosodica trihidratada.
|
US6677320B2
(en)
|
2000-01-20 |
2004-01-13 |
Hoffmann-La Roches Inc. |
Parenteral bisphosphonate composition with improved local tolerance
|
US6476006B2
(en)
|
2000-06-23 |
2002-11-05 |
Teva Pharmaceutical Industries, Ltd. |
Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates
|
KR100327787B1
(ko)
*
|
2001-02-27 |
2002-03-15 |
유승필 |
4-아미노-1-하이드록시부틸리덴-1,1-비스포스폰산 일나트륨 삼수화물의 제조방법
|
US20060269602A1
(en)
*
|
2001-04-13 |
2006-11-30 |
Dasch James R |
Method of modifying the release profile of sustained release compositions
|
US6558702B2
(en)
|
2001-04-13 |
2003-05-06 |
Alkermes Controlled Therapeutics, Inc. |
Method of modifying the release profile of sustained release compositions
|
TR200101250A2
(tr)
*
|
2001-05-10 |
2003-04-21 |
E�S Eczaciba�I �Zg�N K�Myasal �R�Nler Sanay� A.�. |
4-amino-1-hidroksibutiliden-1,1-bifosfonik asit veya tuzlarının hazırlanmasına ilişkin proses
|
GB0115824D0
(en)
*
|
2001-06-28 |
2001-08-22 |
Rhodia Cons Spec Ltd |
Improved solvent systems
|
WO2003055496A1
(en)
*
|
2001-12-21 |
2003-07-10 |
The Procter & Gamble Company |
Method for the treatment of bone disorders
|
CA2472578A1
(en)
*
|
2002-01-24 |
2003-07-31 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Anti-cancer combination and use thereof
|
ITMI20020908A1
(it)
*
|
2002-04-29 |
2003-10-29 |
Chemi Spa |
Processo di preparazione di sodio alendronato
|
KR20120065435A
(ko)
|
2002-05-10 |
2012-06-20 |
에프. 호프만-라 로슈 아게 |
골다공증 치료 및 예방용 비스포스폰산
|
ATE461205T1
(de)
*
|
2002-05-17 |
2010-04-15 |
Teva Pharma |
Verwendung von bestimmten lösungsmitteln zur herstellung von bisphosphonsäuren
|
JP2005534653A
(ja)
*
|
2002-06-06 |
2005-11-17 |
メルク フロスト カナダ アンド カンパニー |
眼及び骨疾患の治療に於いてep4受容体作動薬として使用するための1,5−二置換イミダゾリジン−2−オン誘導体
|
JP4485117B2
(ja)
*
|
2002-06-27 |
2010-06-16 |
日東電工株式会社 |
保護剥離用フィルム
|
EP1545517A1
(de)
*
|
2002-08-28 |
2005-06-29 |
Merck Frosst Canada & Co. |
Oxazolidin-2-on und thiazolidin-2-on-derivate zur verwendung als ep4-rezeptor-agonisten bei der behandlung von glaukom
|
US20040138180A1
(en)
*
|
2002-10-03 |
2004-07-15 |
Barr Laboratories, Inc. |
Bisphosphonate composition and process for the preparation thereof
|
BR0309691A
(pt)
*
|
2002-12-20 |
2005-08-02 |
Hoffmann La Roche |
Formulação de ibandronato em alta dose
|
US20040206932A1
(en)
*
|
2002-12-30 |
2004-10-21 |
Abuelyaman Ahmed S. |
Compositions including polymerizable bisphosphonic acids and methods
|
HUP0300227A2
(hu)
*
|
2003-01-28 |
2004-09-28 |
Richter Gedeon Vegyészeti Gyár Rt. |
Eljárás nagy tisztaságú 2-szubsztituált -1-(hidroxi-etilidén)-1,1-biszfoszfonsavak és sóik előállítására
|
WO2005018581A2
(en)
*
|
2003-08-12 |
2005-03-03 |
3M Innovative Properties Company |
Self-etching dental compositions and methods
|
EP1673336B1
(de)
|
2003-08-21 |
2014-06-04 |
Merck Canada Inc. |
Cathepsincysteinproteasehemmer
|
US7411087B2
(en)
*
|
2003-08-21 |
2008-08-12 |
Sun Pharmaceutical Industries Limited |
Process for preparation of bisphosphonic acid compounds
|
CA2539359A1
(en)
*
|
2003-09-19 |
2005-03-31 |
Pfizer Products Inc. |
Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate
|
WO2005035542A1
(en)
*
|
2003-10-14 |
2005-04-21 |
Pliva-Istrazivanje I Razvoj D.O.O. |
Solid-state form of alendronate sodium and preparation thereof
|
US20050181043A1
(en)
*
|
2004-02-12 |
2005-08-18 |
Indranil Nandi |
Alendronate salt tablet compositions
|
KR20080083068A
(ko)
|
2004-05-24 |
2008-09-12 |
더 프록터 앤드 갬블 캄파니 |
킬레이팅제를 함유하는 비스포스포네이트의 고형의 장용 경구 투여 형태
|
UA87854C2
(en)
|
2004-06-07 |
2009-08-25 |
Мерк Энд Ко., Инк. |
N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
|
CA2573020A1
(en)
*
|
2004-07-08 |
2006-02-09 |
3M Innovative Properties Company |
Dental methods, compositions, and kits including acid-sensitive dyes
|
EP1784155B1
(de)
*
|
2004-08-11 |
2011-09-28 |
3M Innovative Properties Company |
Selbstklebende zusammensetzungen mit einer vielzahl von sauren verbindungen
|
US7361761B2
(en)
*
|
2004-09-28 |
2008-04-22 |
Orchid Chemicals & Pharmaceuticals Ltd. |
Process for the preparation of bisphosphonic acid
|
EP1855674B1
(de)
|
2005-03-02 |
2014-07-16 |
Merck Sharp & Dohme Corp. |
Zusammensetzung zur hemmung von cathepsin k
|
BRPI0606280A2
(pt)
*
|
2005-03-17 |
2009-06-09 |
Elan Pharma Int Ltd |
composições de bisfosfonato nanoparticulado
|
EP1891081B1
(de)
*
|
2005-06-13 |
2014-08-20 |
Jubilant Organosys Limited |
Verfahren zur herstellung von bisphosphonsäuren und formen davon
|
AR054673A1
(es)
|
2005-07-28 |
2007-07-11 |
Gador Sa |
Una forma cristalina del acido zoledronico, un proceso para su obtencion y la composicion farmaceutica que la comprende
|
US8003820B2
(en)
*
|
2005-10-20 |
2011-08-23 |
Dr. Reddy's Laboratories Limited |
Process for preparing bisphosphonic acids
|
ES2323728T3
(es)
|
2005-12-27 |
2009-07-23 |
Ipca Laboratories Limited |
Proceso mejorado para la fabricacion de 4-amino-hidroxibutilideno-1,1-bisfosfonico y sus sales.
|
WO2007083240A2
(en)
|
2006-01-20 |
2007-07-26 |
Aurobindo Pharma Limited |
An improved process for the preparation of bisphosphonic acids
|
WO2007096896A1
(en)
*
|
2006-02-20 |
2007-08-30 |
Alembic Limited |
An improved process for the preparation of biphosphonic derivatives
|
KR20090005206A
(ko)
*
|
2006-05-11 |
2009-01-12 |
인드-스위프트 래버러토리즈 리미티드 |
순수한 리세드론산 또는 염의 제조 방법
|
CA2570949A1
(en)
*
|
2006-12-12 |
2008-06-12 |
Apotex Pharmachem Inc. |
Ibandronate sodium propylene glycol solvate and processes for the preparation thereof
|
EP2101716A2
(de)
*
|
2006-12-13 |
2009-09-23 |
3M Innovative Properties Company |
Verfahren zur verwendung einer dentalen zusammensetzung mit saurer komponente und lichtbleichbarem farbstoff
|
US20090170815A1
(en)
*
|
2007-12-28 |
2009-07-02 |
Roxane Laboratories Incorporated. |
Alendronate oral liquid formulations
|
US8026388B2
(en)
*
|
2008-07-11 |
2011-09-27 |
Synthon Bv |
Process for making 1-hydroxyalkylidene-1,1-biphosphonic acids
|
US20100130746A1
(en)
*
|
2008-11-26 |
2010-05-27 |
Martin Kas |
Process for Making Zoledronic Acid
|
US20120100206A1
(en)
|
2009-06-11 |
2012-04-26 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. |
Targeted liposomes comprising n-containing bisphosphonates and uses thereof
|
EA201270328A1
(ru)
|
2009-08-28 |
2012-09-28 |
Синтон Б. В. |
Способ получения 1-гидроксиалкилиден-1,1-дифосфоновых кислот
|
BR112012007554B1
(pt)
*
|
2009-10-02 |
2018-09-04 |
Monsanto Technology Llc |
método para a fabricação de ácidos amino hidróxi disfofônico
|
CA2738045C
(en)
|
2010-05-28 |
2019-02-19 |
Simon Fraser University |
Conjugate compounds, methods of making same, and uses thereof
|
BR112013010476B1
(pt)
|
2010-12-06 |
2021-07-06 |
Effrx Pharmaceuticals Sa |
formulações efervescentes estáveis de bisfosfonato com características de solubilização rápida
|
EP2675440B1
(de)
|
2011-02-14 |
2020-03-25 |
Merck Sharp & Dohme Corp. |
Cathepsin-cysteinproteasehemmer
|
PL2731591T3
(pl)
|
2011-07-13 |
2021-05-17 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. |
Liposomy zawierające bisfosfonian i środek amfipatyczny w wyniku ko-enkapsulacji
|
WO2015051479A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
CN105593230B
(zh)
|
2013-10-08 |
2018-07-06 |
默沙东公司 |
组织蛋白酶半胱氨酸蛋白酶抑制剂
|
WO2015120580A1
(en)
|
2014-02-11 |
2015-08-20 |
Merck Sharp & Dohme Corp. |
Cathepsin cysteine protease inhibitors
|
PL407922A1
(pl)
|
2014-04-16 |
2015-10-26 |
Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością |
Nowe bisfosfoniany i ich zastosowanie
|
US9650414B1
(en)
|
2014-05-30 |
2017-05-16 |
Simon Fraser University |
Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof
|
KR20160147007A
(ko)
|
2014-05-30 |
2016-12-21 |
화이자 인코포레이티드 |
선택적인 안드로겐 수용체 조절제로서의 카보니트릴 유도체
|
CN107849072B
(zh)
|
2015-06-12 |
2020-12-15 |
西蒙弗雷泽大学 |
酰胺连接的ep4激动剂-二膦酸盐化合物及其用途
|
EP3827010A4
(de)
|
2018-07-23 |
2022-03-16 |
Brise Pharmaceuticals Co., Ltd. |
Bisphosphonat-wirkstoff-konjugate
|
WO2023275715A1
(en)
|
2021-06-30 |
2023-01-05 |
Pfizer Inc. |
Metabolites of selective androgen receptor modulators
|